297 related articles for article (PubMed ID: 17498667)
41. Molecular pathways: old drugs define new pathways: non-histone acetylation at the crossroads of the DNA damage response and autophagy.
Botrugno OA; Robert T; Vanoli F; Foiani M; Minucci S
Clin Cancer Res; 2012 May; 18(9):2436-42. PubMed ID: 22512979
[TBL] [Abstract][Full Text] [Related]
42. Epigenome: a new target in cancer therapy.
Giacinti L; Vici P; Lopez M
Clin Ter; 2008; 159(5):347-60. PubMed ID: 18998037
[TBL] [Abstract][Full Text] [Related]
43. HDAC modulation and cell death in the clinic.
Dell'Aversana C; Lepore I; Altucci L
Exp Cell Res; 2012 Jul; 318(11):1229-44. PubMed ID: 22336671
[TBL] [Abstract][Full Text] [Related]
44. Histone Deacetylase Inhibitors as Anticancer Drugs.
Eckschlager T; Plch J; Stiborova M; Hrabeta J
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
[TBL] [Abstract][Full Text] [Related]
45. Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and Ras.
Chinnaiyan P; Allen GW; Harari PM
Semin Radiat Oncol; 2006 Jan; 16(1):59-64. PubMed ID: 16378908
[TBL] [Abstract][Full Text] [Related]
46. Romidepsin: a novel histone deacetylase inhibitor for cancer.
Bertino EM; Otterson GA
Expert Opin Investig Drugs; 2011 Aug; 20(8):1151-8. PubMed ID: 21699444
[TBL] [Abstract][Full Text] [Related]
47. Differential role of epigenetic modulators in malignant and normal stem cells: a novel tool in preclinical in vitro toxicology and clinical therapy.
Snykers S; Vinken M; Rogiers V; Vanhaecke T
Arch Toxicol; 2007 Aug; 81(8):533-44. PubMed ID: 17387455
[TBL] [Abstract][Full Text] [Related]
48. Emerging role of epigenetic therapies in cutaneous T-cell lymphomas.
Zain J; Kaminetzky D; O'Connor OA
Expert Rev Hematol; 2010 Apr; 3(2):187-203. PubMed ID: 21083462
[TBL] [Abstract][Full Text] [Related]
49. Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?
Karagiannis TC; El-Osta A
Leukemia; 2007 Jan; 21(1):61-5. PubMed ID: 17109024
[TBL] [Abstract][Full Text] [Related]
50. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
Apuri S; Sokol L
Expert Opin Investig Drugs; 2016 Jun; 25(6):687-96. PubMed ID: 26954526
[TBL] [Abstract][Full Text] [Related]
51. HDAC inhibitor-based therapies: can we interpret the code?
New M; Olzscha H; La Thangue NB
Mol Oncol; 2012 Dec; 6(6):637-56. PubMed ID: 23141799
[TBL] [Abstract][Full Text] [Related]
52. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.
Gryder BE; Sodji QH; Oyelere AK
Future Med Chem; 2012 Mar; 4(4):505-24. PubMed ID: 22416777
[TBL] [Abstract][Full Text] [Related]
53. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents.
Tan J; Cang S; Ma Y; Petrillo RL; Liu D
J Hematol Oncol; 2010 Feb; 3():5. PubMed ID: 20132536
[TBL] [Abstract][Full Text] [Related]
54. New patented histone deacetylase inhibitors.
Wang H; Dymock BW
Expert Opin Ther Pat; 2009 Dec; 19(12):1727-57. PubMed ID: 19939190
[TBL] [Abstract][Full Text] [Related]
55. Molecule of the month. Vorinostat.
Drug News Perspect; 2006; 19(6):352. PubMed ID: 16971971
[No Abstract] [Full Text] [Related]
56. Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma.
Zafar SF; Nagaraju GP; El-Rayes B
Expert Opin Ther Targets; 2012 Jul; 16(7):707-18. PubMed ID: 22621256
[TBL] [Abstract][Full Text] [Related]
57. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer.
Thurn KT; Thomas S; Moore A; Munster PN
Future Oncol; 2011 Feb; 7(2):263-83. PubMed ID: 21345145
[TBL] [Abstract][Full Text] [Related]
58. Histone deacetylase inhibitors: understanding a new wave of anticancer agents.
Villar-Garea A; Esteller M
Int J Cancer; 2004 Nov; 112(2):171-8. PubMed ID: 15352027
[TBL] [Abstract][Full Text] [Related]
59. Zinc-dependent Deacetylase (HDAC) Inhibitors with Different Zinc Binding Groups.
Li Y; Wang F; Chen X; Wang J; Zhao Y; Li Y; He B
Curr Top Med Chem; 2019; 19(3):223-241. PubMed ID: 30674261
[TBL] [Abstract][Full Text] [Related]
60. Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents.
Cappellacci L; Perinelli DR; Maggi F; Grifantini M; Petrelli R
Curr Med Chem; 2020; 27(15):2449-2493. PubMed ID: 30332940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
